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1078–5Objectives. To compare the safety and efficacy of a bioresorbable paclitaxel-eluting wrap implanted with a synthetic vas-
cular graft (treatment) versus the graft implanted alone (control).
Design. Prospective, randomized, controlled, multicentre, 2-year clinical study conducted in adults scheduled to undergo
femoropopliteal peripheral bypass surgery with a polytetrafluoroethylene (PTFE) graft.
Materials and methods. Hundred and nine subjects were randomized 2:1 to treatment or control. All subjects were im-
planted with a 6 mm expanded PTFE vascular graft; in addition, treated subjects had a 2.5 cm 4 cm paclitaxel-eluting
wrap (1.6 mg/mm2) placed around the distal graft anastomosis.
Results. The overall incidence of adverse events was similar in both groups. Treated subjects required fewer limb ampu-
tations than controls (15.5% vs 18.4%) and time to amputation for those that required amputation was twice as long (153
days vs 76 days). Among diabetics, this effect was pronounced with 13.8% of treated subjects requiring limb amputations
compared with 23.5% of controls. Over the course of study, the diameter at the distal graft anastomosis was greater in
treated subjects than in controls (difference of 2.1 mm at 2 yr, p¼ 0.03).
Conclusions. The paclitaxel-eluting wrap maintained graft patency at the distal anastomosis and was safe to use in pa-
tients who had received a peripheral bypass PTFE graft.
 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Less than 5% of patients with lower extremity periph-
eral arterial disease (PAD) will progress to critical
limb ischemia (CLI).1 Of those that do, 25% to 40%
will require limb amputation and an additional 20%ancial support: This study was funded by Angiotech Pharma-
ls, Inc., Vancouver, Canada.
onal note: These data were presented at: 1) the European
sium of Vascular Biomaterials (ESVB 2007) 5th annual meet-
pril 26e27, 2007 in Strasbourg, France, and 2) the European
of Vascular Surgery (ESVS) Annual Meeting, September
, 2007 in Madrid, Spain.
sponding author. L. Ma´tya´s, MD, Department of Vascular
y, County Hospital of Miskolc, Szentpe´teri kapu 76, H-3501
lc, Hungary.
address: drml@axelero.hu
884/000715+ 08 $34.00/0  2008 European Society for Vasculato 25% will die within 6 to 12 months of receiving
a CLI diagnosis.2,3 In patients with severe occlusion
and stenosis, and in those with diffuse disease, surgi-
cal bypass may be necessary to restore blood flow and
achieve limb salvage. Typically, a bypass graft is im-
planted from the femoral artery in the groin directly
to the popliteal artery either above or below the
knee.4 In cases where no suitable autologous or other
human veins are available, a synthetic expanded pol-
ytetrafluoroethylene (ePTFE) graft can be used.4 A
persistent complication with this latter approach has
been thrombotic occlusion due to stenosis that de-
velops over the course of 2 or more years as a result
of neointimal hyperplasia at the distal end of the
graft.5e8 At 2 years, only 69% of artery-to-artery
(AA) ePTFE bypass grafts remain patent.6r Surgery. Published by Elsevier Ltd. All rights reserved.
716 L. Ma´tya´s et al.Inhibition of the cellular and biochemical events
that precede the development of neointimal hyper-
plasia has been achieved in a number of studies via
the local delivery of paclitaxel.9e13 These results led
to the development of a perivascular paclitaxel-
eluting wrap (Vascular Wrap, Angiotech Pharma-
ceuticals, Inc. Vancouver, Canada). Paclitaxel elutes
from the wrap over a period of 21 days (data on
file). The wrap itself, which is made from poly(lac-
tide-co-glycolide), fully hydrolyzes in vivo over a pe-
riod of 60 to 90 days.14 In sheep models, the
paclitaxel-eluting wrap was well tolerated and signif-
icantly inhibited neointimal hyperplasia when placed
around the distal anastomosis of both AA ePTFE
grafts as well as artery-to-vein (AV) ePTFE grafts.14,15
This study was designed to investigate the safety and
efficacy of the paclitaxel-eluting wrap implanted with
an ePTFE vascular graft in patients with advanced
PAD, compared to the standard procedure of graft
implanted alone.Table 1. Study selection criteria
Inclusion criteria
provided voluntary written informed consent
18 years of age
diagnosed with PAD with symptoms of chronic limb ischemia
required femoropopliteal peripheral bypass surgery with 6 mm
ePTFE synthetic graft
provided negative pregnancy test
Exclusion criteria
participated in another research study that could interfere with
the purpose of this study
vascular sealant at the application site of the paclitaxel-eluting
wrap
life expectancy of less than one year
prior or current treatment with alkylating agents, current
treatment with cytostats or, within the past year, radiation
colchicine within six months prior to screening
clinically significant cardiac risk factors
immunosuppressant therapy
history of anaphylactic reactions, including reactions to contrast
dyes
intolerance to ASA dosing regimen.Materials and Methods
Overall design and conduct
This 2-year, prospective, single-blind, randomized,
controlled, clinical study was conducted in adults
with PAD and symptoms of chronic limb ischemia
who were selected by their surgeon and scheduled
to undergo femoropopliteal bypass surgery with
a 6 mm ePTFE graft. The control device was a syn-
thetic ePTFE 6 mm vascular graft. The investigational
device was the ePTFE vascular graft plus the biore-
sorbable 2.5 cm 4 cm paclitaxel-eluting wrap
(1.6 mg/wrap; 1.6 mg/mm2), which was placed
around the distal anastomosis immediately following
vascular graft placement and prior to wound closure.
The primary objective was to compare the safety of
the paclitaxel-eluting wrap implanted with a graft
(treatment group) with that of the graft implanted
alone (control group). Other study objectives were to
evaluate the ability of the paclitaxel-eluting wrap to
prevent neointimal hyperplasia by maintaining the in-
ternal diameter of the distal anastomosis and to assess
the overall clinical performance of the paclitaxel-
eluting wrap in the treatment group compared with
controls.
This study was conducted at nine investigational
sites in Hungary, The Netherlands and The Nether-
lands Antilles. Study subjects provided written in-
formed consent prior to their enrollment into this
study. All aspects of the study were governed by the
applicable sections of the International ConferenceEur J Vasc Endovasc Surg Vol 35, June 2008on Harmonisation Guidelines for Good Clinical Prac-
tice (E6), EN ISO 14155 Clinical Investigation of Med-
ical Devices for Human Subjects, the Declaration of
Helsinki of 1964 and its subsequent revisions, and
by the standard operating procedures of all reviewing
ethics committees, contract research organizations,
and the study sponsor.Subjects and randomization
Based upon the length of the study and history of vas-
cular disease, at least 104 subjects were planned to be
enrolled. Eligible participants were included if they
satisfied all inclusion and exclusion criteria (Table 1).
The study employed a 2:1 randomization schedule
of treatment to control subjects. Each investigative
site received a set of numbered computer-generated
sealed randomization envelopes, which were opened
in sequence during the surgery, following hemostasis
at the anastomosis and prior to wound closure. Sub-
jects remained blinded to treatment throughout the
study.Surgery
Using standard surgical technique, the femoral artery
and the popliteal artery were exposed. Blood flow in
the arteries was controlled with vessel loops or vascu-
lar clamps after anti-coagulating the subject according
to the surgeon’s standard procedures. The arterio-
tomy and proximal anastomosis were performed
using standard techniques. The distal end of the
717Paclitaxel-eluting Wrap Prevents Graft Stenosisvascular graft was then connected to the popliteal ar-
tery by an end-to-side anastomosis (distal anastomo-
sis) at approximately 45 angle to the vessel (Fig. 1).
Flushing of the graft and native vessels with heparin
was permitted, if standard practice. The blood flow
was restored. If bleeding occurred at the anastomosis
site, standard operating techniques were used to stop
bleeding. The area was irrigated and aspirated as
needed.
If the subject was randomized to the treatment
group, the backing layer was first removed from
the wrap, and then the wrap was placed around
the distal end of the anastomosis (Fig. 2). The wrap
was positioned to cover the popliteal artery including
the toe and heel of the graft. The wrap was then su-
tured to itself to prevent it from moving from the im-
plantation site. A suture was placed at each of the
opposing corners of the wrap, one slightly proximal
to the arterial anastomosis (behind the heel end of
the graft), and one slightly distal to the anastomosis
(at the toe end of the graft). Care was taken to
minimize excessive handling of the wrap during
application.Fig. 1. Schematic diagram illustrating placement of the
ePTFE graft between the femoral and popliteal arteries
with periadventitial application of the paclitaxel-eluting
wrap to the distal anastomosis.Assessments
Safety, clinical performance and efficacy evaluations,
conducted on the day the subject was discharged
from the hospital, were: a physical examination (af-
fected limb assessment), concomitant medications
query, adverse events (AEs) reporting, and ultrasound
measurements, performed at some sites. These assess-
ments were repeated during subject follow-up visits
at Week 6 and at Months 3, 6, 12, and 18. The same
evaluations were also applied to early discontinua-
tions. At Month 24, safety and performance evalua-
tions included the above-listed assessments and
clinical laboratory tests. At the time that each AE
was reported, the investigator was responsible for: as-
sessing the severity of the event; judging the possible
relatedness of the event to the surgical intervention to
which the patient had been randomized; and, deter-
mining whether the event met the definition for seri-
ous. In this study, an adverse event was defined as
serious (SAE) if it caused death, was life-threatening,
permanently disabling, or required/prolonged hospi-
talization or surgery.Outcome measures
The primary safety measure was reported AEs. All
AEs were coded to a standard set of terms using the
MedDRA v8 AE dictionary, and summarized by sys-
tem organ class and preferred term. Clinical perfor-
mance measures included the amputation rate and
time to amputation. The internal diameter of the distal
graft anastomoses, as measured by ultrasound, served
as the primary efficacy measure.Statistical considerations
Based on data derived from animal studies of the pac-
litaxel-eluting wrap and from human studies of pacli-
taxel-eluting stents, it was estimated that treated
subjects in our study would develop approximately
20% less stenosis at the distal anastomosis than con-
trol subjects. This reduction in stenosis roughly trans-
lates to a 20% difference between groups in the mean
diameter of the distal anastomosis e i.e., a mean dif-
ference of 1.2 mm (20% of 6 mm). Using a t-test of
two independent samples with an a¼ 0.05 level of
significance and assuming a standard deviation in
the diameter of the distal anastomosis of 1.2 mm,
a sample of 56 treated subjects and 28 control subjects
(i.e., a 2:1 randomization) would confer a 95% power
to detect the expected difference between groups. An
additional 20 patients were included to accommodateEur J Vasc Endovasc Surg Vol 35, June 2008
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Fig. 2. CONSORT flow diagram.
718 L. Ma´tya´s et al.a 15% to 30% drop-out rate that was expected in sub-
jects undergoing above-the-knee surgery for PAD.
Descriptive statistics were performed on all demo-
graphic, safety, and performance variables. Safety was
assessed by comparing the frequencies of AEs, SAEs
and AEs judged to be related to the surgical interven-
tion. No formal statistical tests were planned or
performed on any of the demographic or safety vari-
ables; this study was not designed to detect quantita-
tive differences in these measures. Given that
substantial research exists showing paclitaxel pre-
vents neointimal hyperplasia, an assumption of non-
inferiority of treatment compared with control was
made. The hypothesis was that the mean distal diam-
eter after two years post-implantation of the paclitaxel
wrap and graft would not be inferior to the mean dis-
tal diameter of the graft alone, and thus an unpaired
one-tail t-test was used to compare the internal diam-
eters of distal anastomoses at 24 months between the
two groups at the 5% level. For this comparison,Eur J Vasc Endovasc Surg Vol 35, June 2008baseline was defined as the day of discharge or Day
14 post-implantation. For those subjects with amissing
baseline measurement, the average of all subjects with
a baseline for that treatment group was used as the
baseline value. For those subjects with missing post-
baseline values, the last observation was carried for-
ward (LOCF) for subsequent visits until the next visit
where measurements were assessed or until the last
visit. While a t-test was used in order to keep methods
consistent with the sample size discussion in the
study protocol, tests for normality (Shapiro Wilk)
and for homogeneity of variances (Levene for the
time-to amputation) indicated that the distal diameter
data did not fulfill these assumptions. Thus, a second-
ary analysis was performed comparing the internal
diameters of the distal anastomosis at 24 months us-
ing a non-parametric method (the Mann-Whitney
test) with no interpolation for missing values. Note
that this study was not powered to allow for sub-
group analyses based on demographic or other
719Paclitaxel-eluting Wrap Prevents Graft Stenosisbaseline characteristics, and thus a Kruskall-Wallis
test for comparing more than two subgroups was
not performed.Results
Subjects
The study was initiated on September 29, 2003 e the
date of the first visit of the first patient; the study com-
pleted on 31 January 2006 e the date of the last visit of
the last patient. A total of one hundred nine (109) sub-
jects were assessed for eligibility, enrolled and ran-
domized in this study (Fig. 2): 71 to the treatment
group and 38 to the control group. A total of 52 sub-
jects, 37 treated subjects and 15 control subjects, dis-
continued during the study. Of the discontinued
subjects, 15 died during the study (8 treated subjects,
11.3% and 7 controls, 18.4%), 2 treated subjects were
lost to follow-up, and 35 discontinued due to AEs.
For the most part, subjects in the treatment and
control groups had similar demographic and baseline
characteristics (Table 2). Consistent with the preva-
lence of PAD in the overall population, males predo-
minated in this study, accounting for 77.5% of
treated subjects and 84.2% of controls. The median
age was approximately 63 years. Risk factors for
PAD were prevalent among both populations. Cur-
rent or former smokers represented 79% of treated
subjects (56/71) and 87% of controls (33/38). Diabetes
was present in 41% of treated subjects and 45% of con-
trols, and hypertension was a factor in 80% of treated
subjects and 74% of controls. The percentage of previ-
ous vascular procedures (69%) was high in both
groups. Of particular note, the incidence of hypercho-
lesterolemia was markedly higher among treated sub-
jects (47% versus 26% of controls) and this wasTable 2. Summary of demographic and other baseline
characteristics
Paclitaxel-eluting
wrap (N¼ 71)
Control
(N¼ 38)
Gender: n (%)
Male 55 (77.5) 32 (84.2)
Female 16 (22.5) 6 (15.8)
Median Age: (years) 62.6 63.9
Smoking Habit: n (%)
Currently 25 (35.2) 20 (52.6)
Never 15 (21.1) 5 (13.2)
Stopped 31 (43.7) 13 (34.2)
Vascular risk factors: n (%)
Hypertension 57 (80.3) 28 (73.7)
Hypercholesterolemia 33 (46.5) 10 (26.3)
Prior cardiac and vascular
procedures: n (%)
49 (69.0) 26 (68.4)
Diabetes: n (%) 29 (40.8) 17 (44.7)reflected in the incidence of statin use (45% vs 34%
of controls).Safety
The overall incidences of AEs and SAEs were compa-
rable in the treatment and control groups (Table 3);
they also were not markedly different between groups
when events were coded by system organ class and
preferred term. Of particular interest, the incidence
of major thrombotic events (ie., vascular graft occlu-
sion, graft thrombosis) was similar in both groups;
graft complications more commonly occurred in the
control group. As early as 6 months after device im-
plantation, 52% of each group had SAEs, reflecting
the severity of PAD in the study population. After
24 months, 83% and 84% of treated and control sub-
jects respectively had reported AEs; 75% and 68% of
subjects in each group had reported SAEs. No AEs
or SAEs were considered by the investigators to be re-
lated to the use of the investigational device. AEs
leading to death occurred in 11% (8/71) of treated
subjects and in 18% (7/38) of controls. Overall, actions
taken to resolve AEs were similar for the two groups,
and outcomes were comparable. Graft infection oc-
curred in a small percentage of treated subjects (7%,
5/71); there were no reports of graft infection in con-
trol subjects. The five cases that were reported in
treated subjects were clustered in three of the nine in-
vestigational sites (2 at Site 1, 2 at Site 6, and one at
Site 11). Of note, the occurrences at Sites 1 and 2
were observed within the span of a few days. Also,
one patient had a post-implant embolectomy proce-
dure and then angiogram, providing a source for in-
troducing infection. Three cases had initial evidence
of local skin or incision infection which appeared to
have spread to the graft. One case reported swellingTable 3. Summary of all adverse events
Paclitaxel-eluting
wrap (N¼ 71)
Control
(N¼ 38)
n (percent)
All AEs e 24 months 59 (83.1) 32 (84.2)
All AEs e 12 months 55 (77.5) 30 (78.9)
AEs related to the
paclitaxel-eluting wrap
0 (0.0) NA
SAEs e 24 months 53 (74.6) 26 (68.4)
AEs leading to death 8 (11.3) 7 (18.4)
Thrombotic AEs* 42 (59.2) 23 (60.5)
Vascular graft occlusion 30 (42.3) 14 (36.8)
Graft thrombosis 8 (11.3) 5 (13.2)
Vascular graft complication 3 (4.2) 4 (10.5)
AE¼ adverse event; SAE¼ serious adverse event.
* captured under the system organ class of Injury, Poisoning and
Procedural Complications.
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The paclitaxel-eluting wrap had a positive effect on
the number of amputations of the treated limb, the
time to amputation, and the relationship of amputa-
tion to diabetes (Table 4). The incidence of amputation
in the treatment group was 15.5% versus 18.4% in the
control group. Among the subset of patients that
needed a limb amputation, the time to amputation
for treated subjects was twice as long (153 days) as
that for control subjects (76 days). Among diabetics
in the study population; amputation was required in
13.8% of treated diabetic subjects, compared with
23.5% of control diabetic subjects.Efficacy
The mean diameter of the distal anastomosis in the
control group decreased over 24 months (Fig. 3). In
contrast, the mean diameter of the distal anastomosis
in the treatment group was maintained throughout
the 24 months. In powering the study, the expected
mean difference between the treatment and control
groups was 1.2 mm. The difference in observed
mean diameter between treatments was 2.06 mm;
this difference was statistically significant when
assessed using the primary method of analysis, an
unpaired one-tail t-test with the LOCF ( p¼ 0.033).
The difference between mean diameters was also
statistically significant when assessed using the non-
parametric Mann-Whitney test with no interpolation
for missing values ( p¼ 0.034). A power of 94%, deter-
mined post priori, confirmed that the study size was
appropriate for this endpoint and strengthens the
conclusion that the differences in the distal diameters
observed at 2 years post-implantation were
significant.Table 4. Summary of amputation outcomes
Paclitaxel-eluting
wrap (N¼ 71)
Control
(N¼ 38)
Number of amputations (n, percent) 11 (15.5) 7 (18.4)
Number of amputations among
the diabetic population* (n, percent)
4 (13.8) 4 (23.5)
Mean time to amputation (days) 152.6 76.3
* 46 diabetics participated in this study: 29 had been randomized
to receive the paclitaxel-eluting wrap and 17 had been randomized
to receive the standard of care.
Eur J Vasc Endovasc Surg Vol 35, June 2008Discussion
This study was conducted in patients with symptoms
of chronic limb ischemia who required femoropopli-
teal peripheral bypass surgery with a 6 mm ePTFE
graft. Typical of a severe PAD population, most
subjects had multiple risk factors for PAD: 82% were
current or former smokers, 78% were hypertensive,
40% had hypercholesterolemia, and 42% were dia-
betic. And, as might be expected from a population
with such a poor prognosis, the percent of subjects re-
porting AEs (83%) and SAEs (72%) including death
was high. Interestingly, the proportion of AEs that
led to death was less in treated subjects (11%) than
in controls (18%). The incidence of death among con-
trol subjects more closely approached the 6-month to
1-year mortality rates (20% to 25%) reported in the
literature for unselected patients with critical limb
ischemia.3
Overall, the adverse event data demonstrate that
the ePTFE vascular graft implanted with the pacli-
taxel-eluting wrap was safe to use in patients requir-
ing femoropopliteal bypass surgery. The reported
incidences of adverse events and serious adverse
events among those receiving a wrap were compara-
ble to those of the control group. Furthermore, no
adverse events were judged to be related to the pacli-
taxel-eluting wrap. Graft infection occurred only in
treated subjects (7%, 5/71), which was within the
range of infection (0.7e12%) that has been reported
with ePTFE grafts for the general population.16e18
A limitation of our study is that the etiology of
thrombotic adverse events study was often unclear.
When a graft occluded but the etiology was unknown,
it was captured as an occlusion. Graft occlusions were
reported for a similar percentage of treated and con-
trol subjects (42.3%, 30/71 vs 36.8%, 14/38). Without
angiographic evidence collected at the time that the
721Paclitaxel-eluting Wrap Prevents Graft Stenosisocclusion is evolving, it is often difficult to determine
the exact reason for occlusion or the location of where
the problem started. In addition, since we did not
require that the length of the implanted graft be re-
corded, we were unable to determine whether there
were differences between groups in this regard.
Among subjects who received the paclitaxel-
eluting wrap, the mean diameter at the distal graft
anastomosis remained stable throughout the 2-year
study, likely as a result of suppression of neointimal
hyperplasia as evidenced in preclinical models.14,15
In contrast, the control group exhibited decreasing di-
ameter of the distal graft anastomosis over the same
interval. At 2 years, the difference between groups
was statistically significant. Interestingly, clinical
studies that looked at paclitaxel delivery to the coro-
nary artery from the inside of the vessel also demon-
strated suppression of neointimal hyperplasia.19,20 It
should be noted that bias may have been introduced
due to an imbalance in baseline use of statins between
groups, with the treatment arm having 32% higher
statin use (45% and 34% for treated and control sub-
jects, respectively). This difference was most likely
a reflection of the fact that more subjects with hyper-
cholesterolemia were inadvertently enrolled in the
treated group, which had more hypercholesterolemic
patients (47% vs 26% for control subjects). Our study
was not sufficiently powered to account for differ-
ences such as these.
It should be acknowledged that some statins have
been shown in in vitro studies 21 to have a significant
inhibitory effect on the hepatic metabolism of pacli-
taxel. One might speculate that paclitaxel’s effects
could have been amplified in treated subjects who
were hypercholesterolemic and thus using statins.
However, given the wrap formulation used, this
relationship seems unlikely. First, the dose of drug
(1.6 mg) contained in the paclitaxel-eluting wrap
was approximately 140 fold less than what is admin-
istered in a single systemic dose to a 50-kg oncology
patient. Second, we know from unpublished animal
studies that no detectable levels of paclitaxel were
found in the systemic circulation even at the highest
dose tested (1.2 mg/wrap).14 Thus, it is unlikely that
the action of paclitaxel in our study was impacted
by the hepatic activity of statins or that hypercholes-
terolemic patients in the treatment group unduly
benefited from their statin use.
Amputations occurred in a proportion of the con-
trol subjects as one might expect in this severely
diseased population. However, the incidence of am-
putations was less with the use of the paclitaxel-
eluting wrap, and the time to amputation for those
that required amputation was prolonged 2-fold.Extrapolating from the known effect of paclitaxel es-
tablished in various preclinical studies,9e13 this result
suggests that the paclitaxel-eluting wrap prevented
the development of neointimal hyperplasia, allowing
better perfusion of the lower extremity, contributing
to the reduction in amputation rate and prolongation
of time to amputation. With diabetic subjects, the ef-
fect on limb retention was even more profound;
a 41% reduction over the 2-year amputation rate
was observed in the diabetics who received the
wrap compared with diabetics who did not. This con-
ferred benefit is particularly relevant given that diabe-
tes so dramatically increases (up to 15 fold compared
with non-diabetics) the risk of amputation among
patients with lower extremity PAD.3,22
Conclusions
This trial provided clinical evidence for the safety and
efficacy of the paclitaxel-eluting wrap implanted with
an ePTFE vascular graft in arterial bypass surgery
necessitated by peripheral vascular disease:
 The incidences of non-serious and serious adverse
events were comparable in treatment (graft with
paclitaxel-eluting wrap) and control (graft alone)
groups;
 No adverse events were considered related to the
use of the paclitaxel-eluting wrap;
 The paclitaxel-eluting wrap maintained the mean
diameter of the distal anastomosis throughout
the 24 months compared with a decreasing mean
diameter in controls; the difference was statisti-
cally significant at 2 years.
Furthermore, the paclitaxel-eluting wrap reduced
the incidence of amputation, and prolonged by two-
fold the time to amputation for those that required
amputation. This effect was pronounced among
diabetic subjects.
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